We administered a lower dose of survivin siRNA for anti-tumor proliferation experiments in vivo (a 15 μg of siRNA/injection, 7 times; total of 135 μg) relative to other systemic drug delivery systems for solid tumors [45–47], including cationic Lipofection complex (11.1-fold; 150 μg of siRNA/injection, 10 times), atelocollagen/siRNA (8.9-fold; 100 μg of siRNA/injection, 12 times), and clinically tested cyclodextrin-based polymer CALAA-01 (3.0–5.9-fold; 100–200 μg of siRNA/injection, 4 times). The gene discussed is BIRC5; the disease is neoplasm.